T
Tuula Lehtinen
Researcher at University of Tampere
Publications - 38
Citations - 2882
Tuula Lehtinen is an academic researcher from University of Tampere. The author has contributed to research in topics: Odds ratio & Lymphoma. The author has an hindex of 20, co-authored 38 publications receiving 2715 citations.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh,Lorenz Trümper,Anders Österborg,Ruth Pettengell,Marek Trneny,Kevin Imrie,David D.F. Ma,Devinder Gill,Jan Walewski,Pier Luigi Zinzani,Rolf A. Stahel,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Tuula Lehtinen,Armando López-Guillermo,Claudia Corrado,Adriana Scheliga,Noel Milpied,Myriam Mendila,Michelle Rashford,Evelyn Kuhnt,Markus Loeffler +23 more
TL;DR: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Journal ArticleDOI
Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring.
Matti Lehtinen,Pentti Koskela,Helga M. Ögmundsdóttir,Aini Bloigu,Joakim Dillner,Margrét Gudnadóttir,Timo Hakulinen,Anne Kjartansdottir,Matias Kvarnung,Eero Pukkala,Hrafn Tulinius,Tuula Lehtinen +11 more
TL;DR: Assessment of the relative role of three maternal herpesvirus infections in childhood acute lymphoblastic leukemia indicates that reactivation of maternal EBV infection is probably associated with childhood ALL.
Journal ArticleDOI
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.
Eva Kimby,Jesper Jurlander,Christian H. Geisler,Hans Hagberg,Harald Holte,Tuula Lehtinen,Bjørn Østenstad,Mads Hansen,Anders Österborg,Ola Lindén,Christer Sundström +10 more
TL;DR: Extended rituximab is effective and well tolerated and combination with IFN seems to improve both the quality and duration of the responses, providing the opportunity to achieve long-term molecular CRs and prolonged failure-free survival without chemotherapy.
Journal ArticleDOI
Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.
Esa Jantunen,Tom Wiklund,Eeva Juvonen,Mikko Putkonen,Tuula Lehtinen,Outi Kuittinen,Kaarle Franssila,K O Soderstrom,Sirpa Leppä,Sirpa Leppä,Erkki Elonen,Kari Remes,Tapio Nousiainen +12 more
TL;DR: Prospective studies are needed to define the role of ASCT in this lymphoma type, as limited experience is available on the feasibility and efficacy of high-dose therapy supported by autologous stem cell transplantation in patients with peripheral T-cell lymphoma.
Journal ArticleDOI
Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients.
Esa Jantunen,Salonen J,Eeva Juvonen,E. Koivunen,Timo Siitonen,Tuula Lehtinen,Outi Kuittinen,Sirpa Leppä,Sirpa Leppä,Veli-Jukka Anttila,Maija Itälä,Tom Wiklund,Kari Remes,Tapio Nousiainen +13 more
TL;DR: IFI appears to be a rare event after ASCT and Aspergillus infections seem to be predominant and these epidemiological features have an impact in planning prophylactic and empirical antifungal strategies in ASCT recipients.